Stockscreener 앱 받기
21.18
1.26%
-0.27
시장 영업 전:
21.18
Arrivent Biopharma Inc 주식(AVBP)의 최신 뉴스
News impact scoring models applied to ArriVent BioPharma Inc.AI-Based Reversal Point Prediction Signal - Newser
Using data models to predict ArriVent BioPharma Inc. stock movement Low Risk Trade Timing with Analysis Metrics - Newser
ArriVent BioPharma Inc. recovery potential after sell off Price Action Based Buy Zone Forecast - Newser
Is ArriVent BioPharma Inc. a growth stock or a value stockAchieve consistent double-digit returns - jammulinksnews.com
What is ArriVent BioPharma Inc. company’s growth strategyBuild a winning investment strategy - jammulinksnews.com
What institutional investors are buying ArriVent BioPharma Inc. stockFree Daily Trading Room Entry - jammulinksnews.com
How strong is ArriVent BioPharma Inc. company’s balance sheetUnlock real-time stock alerts for quick profits - jammulinksnews.com
Is ArriVent BioPharma Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
How many analysts rate ArriVent BioPharma Inc. as a “Buy”Exceptional trading performance - jammulinksnews.com
What makes ArriVent BioPharma Inc. stock price move sharplyOptimized Return Investment Picks - Newser
ArriVent BioPharma Inc. Company’s Quarterly Earnings Growth: What the Numbers SaySteady Profit Stock Forecasts - Newser
ArriVent BioPharma Inc. Earnings Report Breakdown: What Investors Should KnowFree Stock Portfolio Optimization - Newser
Is ArriVent BioPharma Inc. stock a growth or value playLow Risk Trade Timing Signals - Newser
ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data - MSN
ArriVent BioPharma Inc. Stock Analysis and ForecastExceptional market positioning - PrintWeekIndia
What risks could impact ArriVent BioPharma Inc. stock performanceLightning-fast capital gains - jammulinksnews.com
Lifesci Capital Issues Positive Estimate for AVBP Earnings - Defense World
Can ArriVent BioPharma Inc. stock recover from recent declineUnprecedented market success - jammulinksnews.com
What analysts say about ArriVent BioPharma Inc. stockExplosive returns - PrintWeekIndia
Is ArriVent BioPharma Inc. a good long term investmentPowerful market insights - Autocar Professional
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of “Buy” from Analysts - Defense World
ArriVent BioPharma, Inc. (AVBP) Receives a Buy from B.Riley Financial - The Globe and Mail
ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
What drives ArriVent BioPharma Inc. stock priceAccelerated wealth expansion - jammulinksnews.com
ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating By Investing.com - Investing.com Canada
ArriVent Biopharma announces data from its FURVENT Phase 3 study - TipRanks
ArriVent expects topline data from lung cancer drug trial in early 2026 - Investing.com Canada
ArriVent expects topline data from lung cancer drug trial in early 2026 By Investing.com - Investing.com South Africa
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - The Manila Times
New Strong Sell Stocks For July 21st - Barchart.com
New Strong Sell Stocks for July 21st - The Globe and Mail
P 500Low Risk Trade Timing Signals - Newser
0.97%
0.22%
자본화:
|
볼륨(24시간):